Research / JOUT / Fundamental state Inspectable configuration
State dimensions Filing 0000788329-26-000016 General Corporate
Debt relative to revenue 100th Own-history percentile · N=16
Evidence method Level · gp.fundamentals.debt_to_revenue
0.00% · OPTIONAL · VALID
Capex intensity 38th Own-history percentile · N=16
Evidence method Level · gp.fundamentals.capex_revenue_ratio
3.09% · OPTIONAL · VALID
Operating cash generation 94th Own-history percentile · N=16
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
40.95% · OPTIONAL · VALID
Revenue growth 75th Own-history percentile · N=12
Evidence method Yoy · gp.fundamentals.revenue
5.02% · CORE · VALID
Inventory pressure 31th Own-history percentile · N=16
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
99.23% · OPTIONAL · VALID
Gross margin 100th Own-history percentile · N=16
Evidence method Level · gp.fundamentals.gross_margin
45.29% · CORE · VALID
Operating margin 94th Own-history percentile · N=16
Evidence method Level · gp.fundamentals.operating_margin
9.67% · CORE · VALID
R&D intensity 50th Own-history percentile · N=16
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
4.58% · OPTIONAL · VALID
SBC intensity 75th Own-history percentile · N=16
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
0.50% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 17 states Self-history eligible
Apr 1, 2022 0/8 normalized Level 3 Jul 1, 2022 0/8 normalized Level 3 Dec 30, 2022 0/8 normalized Level 3 Mar 31, 2023 0/9 normalized Level 3 Jun 30, 2023 0/9 normalized Level 3 Sep 29, 2023 0/8 normalized Level 3 Dec 29, 2023 0/9 normalized Level 3 Mar 29, 2024 0/9 normalized Level 3 Jun 28, 2024 8/9 normalized Level 3 Sep 27, 2024 8/9 normalized Level 3 Dec 27, 2024 8/9 normalized Level 3 Mar 28, 2025 8/9 normalized Level 3 Jun 27, 2025 9/9 normalized Level 3 Oct 3, 2025 9/9 normalized Level 3 Jan 2, 2026 9/9 normalized Level 3 Apr 3, 2026 9/9 normalized Level 3 Jul 3, 2026 9/9 normalized Level 4 Period transition
What moved in the state? Capex Intensity Decreased
Previous 3.19%
Current 3.09%
Delta -0.10% Cash Generation Increased
Previous -6.32%
Current 40.95%
Delta 47.27% Growth Decreased
Previous 15.52%
Current 5.02%
Delta -10.50% Inventory Pressure Increased
Previous 96.10%
Current 99.23%
Delta 3.12% Margin Increased
Previous 38.82%
Current 45.29%
Delta 6.48% Profitability Increased
Previous 5.32%
Current 9.67%
Delta 4.35% R And D Intensity Increased
Previous 4.41%
Current 4.58%
Delta 0.17% Sbc Intensity Increased
Previous 0.49%
Current 0.50%
Delta 0.02% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Apr 3, 2026
Similarity 80%
Compared 9 dimensions
Coverage 100% Growth 15.9 · Margin 6.7 · Profitability 20.4 · Sbc Intensity 1.7 · Capex Intensity 2.5 · Cash Generation 53.8 · R And D Intensity 3.3 · Inventory Pressure 4.6 · Balance Sheet Leverage 0.0 Jun 27, 2025
Similarity 69%
Compared 9 dimensions
Coverage 100% Growth 12.5 · Margin 16.7 · Profitability 27.1 · Sbc Intensity 75.0 · Capex Intensity 29.2 · Cash Generation 2.1 · R And D Intensity 25.0 · Inventory Pressure 14.6 · Balance Sheet Leverage 0.0 Jun 28, 2024
Similarity 52%
Compared 8 dimensions
Coverage 89% Margin 75.0 · Profitability 93.8 · Sbc Intensity 50.0 · Capex Intensity 12.5 · Cash Generation 6.3 · R And D Intensity 0.0 · Inventory Pressure 31.3 · Balance Sheet Leverage 0.0 Dec 27, 2024
Similarity 33%
Compared 8 dimensions
Coverage 89% Margin 100.0 · Profitability 93.8 · Sbc Intensity 15.0 · Capex Intensity 42.5 · Cash Generation 93.8 · R And D Intensity 50.0 · Inventory Pressure 58.8 · Balance Sheet Leverage 0.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.